Join us on 12-15-2022 for a live seminar about RNA SEQ
Our Discovery Services augment your own expertise or give you capacity when you need it. Our team of leading scientists runs bespoke drug discovery campaigns for our partners and is continually innovating to validate and utilize cutting edge technology in our discovery offerings.
DeepImmune combines Alloy’s rapidly expanding family of ATX-Gx™ humanized mouse strains with advanced immunization strategies, custom antibody libraries, and machine learning-generated insights and libraries to generate highly diverse immune responses to even the most challenging antigens.
Our DeepImmune process captures the full diversity of antigen specific B-cells through sophisticated single cell technologies, immune phage libraries, and proprietary hybridoma protocols—all supported by next generation sequencing and deep learning-assisted immune repertoire analysis.
The DeepImmune process uses an iterative design, test, learn feedback model to characterize and assess the biophysical and functional properties of your antibody hits to identify your top lead candidates by merging antibody-specific analytical methods with functional characterization and developability assessment, enabled by machine learning engine for sequence data mining.
Click image to enlarge
We accelerate partner programs by providing early insights into functional activity of therapeutic candidates generated from Alloy discovery programs across all modalities. Generally, we offer these services in line with DeepImmune for human antibody discovery and Keyway for therapeutic TCR discovery, but we can offer advice and services on a case-by-case basis for our license partners and ecosystem collaborators.
We democratize access to foundational, pre-competitive biologics discovery technologies and services.
Case Studies:
